Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Myeloproliferative disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Myeloproliferative disease. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2007-006694-91 Sponsor Protocol Number: FARM6YNXAN Start Date*: 2008-05-23
    Sponsor Name:G.I.M.E.M.A.
    Full Title: A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV) – CYTO-PV.
    Medical condition: Polycytemia vera
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028576 Myeloproliferative disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002253-30 Sponsor Protocol Number: SVT-RUXO#2012 Start Date*: 2012-10-04
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI FIRENZE
    Full Title: A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Medical condition: splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001406-42 Sponsor Protocol Number: 30032016 Start Date*: 2016-12-20
    Sponsor Name:Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde
    Full Title: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.
    Medical condition: The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028577 Myeloproliferative disorder NOS LLT
    19.0 100000004864 10074689 Post polycythemia vera myelofibrosis LLT
    19.0 100000004864 10028576 Myeloproliferative disorder LLT
    19.0 100000004864 10074692 Post essential thrombocythaemia myelofibrosis LLT
    19.0 100000004864 10074690 Post essential thrombocythemia myelofibrosis LLT
    19.0 100000004864 10074691 Post polycythaemia vera myelofibrosis LLT
    19.0 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    19.0 100000004864 10015495 Essential thrombocytosis LLT
    19.0 100000004864 10015494 Essential thrombocythemia LLT
    19.0 100000004864 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005497-38 Sponsor Protocol Number: RG_15-234 Start Date*: 2016-05-25
    Sponsor Name:University of Birmingham
    Full Title: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms
    Medical condition: Myeloproliferative Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028576 Myeloproliferative disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003499-37 Sponsor Protocol Number: DSC/11/2357/44 Start Date*: 2013-01-20
    Sponsor Name:ITALFARMACO
    Full Title: Long-term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.
    Medical condition: Chronic myeloproliferative neoplasms (cMPN).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10028578 Myeloproliferative disorders (excl leukaemias) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003171-39 Sponsor Protocol Number: T-Control Start Date*: 2016-03-08
    Sponsor Name:University Hospital Wuerzburg
    Full Title: Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation
    Medical condition: patients with hematological malignancies after T cell depleted allo-SCT
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000846 Acute lymphocytic leukaemia PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028576 Myeloproliferative disorder PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025311 Lymphoma (non-Hodgkin's) LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006647-45 Sponsor Protocol Number: D1060C00001 Start Date*: 2009-05-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary ...
    Medical condition: Myeloproliferative disorders including Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028578 Myeloproliferative disorders (excl leukaemias) HLT
    9.1 10036057 Polycythaemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003009-31 Sponsor Protocol Number: HH007 Start Date*: 2022-12-23
    Sponsor Name:Zealand University Hospital, dept. of Haematology
    Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis
    Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003392-17 Sponsor Protocol Number: BUSEQ-IPC2020-006 Start Date*: 2021-02-17
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: SEQUENTIAL AND PERSONALIZED BUSULFAN ADMINISTRATION BY PHARMACOKINETICS IN ALLOGENIC GRAFT CONDITIONING FOR PATIENTS WITH MALIGNANT HEMOPATHIA NOT ELIGIBLE FOR STANDARD MYELOABLATIVE PACKAGIN
    Medical condition: Acute Leukemia Mielodysplasic Syndrome Myeloproliferative Neoplasm
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002141-11 Sponsor Protocol Number: Vedolizumab-3035 Start Date*: 2018-11-08
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Und...
    Medical condition: Intestinal acute graft-versus-host disease (aGvHD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) DE (Completed) AT (Completed) PL (Completed) ES (Completed) PT (Completed) BE (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-010738-23 Sponsor Protocol Number: MPN-SG01-09 Start Date*: 2009-11-12
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage
    Medical condition: This is a phase II, multi-center study of pomalidomide in adult patients with Primary myelofibrosis, Secondary myelofibrosis, and unclassifiable Myeloproliferative Neoplasms showing at least grade ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005214-21 Sponsor Protocol Number: RuNiC. Start Date*: 2017-07-17
    Sponsor Name: Grupo Español de Enfermedades Mieloproliferativas GEMFIN
    Full Title: Phase Ib/II clinical trial of ruxolitinib in combination with nilotinib and prednisona for myelofibrosis: RuNiC study
    Medical condition: Myeloproliferative Diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10074691 Post polycythaemia vera myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002042-32 Sponsor Protocol Number: CPX-351-TA-SMP Start Date*: 2021-09-16
    Sponsor Name:FILO
    Full Title: A phase II study of CPX-351 monotherapy in Acute Myeloid Leukemia secondary to Myeloproliferative neoplams
    Medical condition: newly secondary AML according to WHO 2016 classification following an antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET), Polycythemia Vera (PV), primary or secondar...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000614-39 Sponsor Protocol Number: 2016/9408 Start Date*: 2017-03-22
    Sponsor Name:OSLO UNIVERSITY HOSPITAL HF
    Full Title: Prevention of graft-versus-host disease in patients treated with allogeneic stem cell transplantation: Possible role of extracorporeal photophoresis
    Medical condition: Graft-versus-host disease (GVHD), both acute and chronic untill one year after allogeneic stam cell transplatation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012784-34 Sponsor Protocol Number: 384/09 Start Date*: 2009-07-08
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: STUDY OF HYDROXYUREA MECHANISMS OF ACTION ON LEUKOCYTE ACTIVATION IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE SYNDROMES.
    Medical condition: MYELOPROLIFERATIVE SYNDROMES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015493 LLT
    9.1 10036057 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002431-29 Sponsor Protocol Number: POMINC(MPNSG02-12) Start Date*: 2013-07-23
    Sponsor Name:University Hospital of Ulm
    Full Title: A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis
    Medical condition: Patients with Primary and Secondary Myelofibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001012-56 Sponsor Protocol Number: I3X-MC-JHTB Start Date*: 2012-08-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
    Medical condition: Myeloproliferative neoplasms (MPNs), myelofibrosis, essential thrombocythemia, and polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036061 Polycythemia vera LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) SE (Completed) AT (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003650-23 Sponsor Protocol Number: KKSH178 Start Date*: 2022-07-29
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis
    Medical condition: Myeloproliferative neoplasm in accelerated phase (MPN-AP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001076-34 Sponsor Protocol Number: ABNL-MARRO-001 Start Date*: 2023-06-12
    Sponsor Name:Theradex (Europe) Ltd.
    Full Title: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
    Medical condition: Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018965-42 Sponsor Protocol Number: CC-4047-MF-002 Start Date*: 2010-11-03
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE-3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE EFFICACY AND SAFETY OF POMALIDOMIDE IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM -ASSOCIATED M...
    Medical condition: Myeloproliferative Neoplasm (MPN) Associated Myelofibrosis defined as primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF) and post-essential thrombocythemia myelofibrosis...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) AT (Completed) IT (Completed) ES (Completed) BE (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 13:15:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA